BIOMARIN PHAR. DL-,001 | 68,45 / +2,76% |
Fecha/Hora | 15.01. / 19:30 |
Dif. / Dif.(%) | 1,84 / +2,76% |
Bid | - |
Ask | - |
Apertura | 66,71 |
Cierre del día anterior | 66,61 |
Máxima sesión | 68,45 |
Mínima sesión | 66,65 |
Volumen [EUR] | 0,00 |
Volumen [Unidades] | 0 |
Fijación de precios | 20 |
ISIN | US09061G1013 |
Símbolo | BM8 |
Bolsa | Düsseldorf |
Tipo | Stock |
Otras Bolsas
Bolsa | Último | Volumen | |
---|---|---|---|
NASDAQ | 82,9700 | ![]() |
1.306.558 |
Cboe US | 82,85 | ![]() |
89.343 |
IEX | 82,89 | ![]() |
62.135 |
TradeGate | 68,200 | ![]() |
988 |
Vienna Globa.. | 68,08 | ![]() |
849 |
gettex | 69,110 | ![]() |
70 |
Frankfurt | 67,7500 | ![]() |
64 |
Xetra | 68,08 | ![]() |
0 |
Berlin | 66,75 | ![]() |
0 |
München | 67,07 | ![]() |
0 |
Düsseldorf | 68,45 | ![]() |
0 |
Stuttgart | 68,800 | ![]() |
0 |
Lang & Schwa.. | 67,95 | ![]() |
|
Mexico | 1.599,31 | ![]() |
4.200 |
London Inter.. | 81,84 | 295 |
Noticias
- BioMarin sinks 32% as FDA delays its hemophilia treatment
19.08.2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
28.04.2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12.12.2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
23.11.2015 / 16:59 - GlobeNewswire